Actuate Therapeutics Inc
ACTU6.780USD
-0.200-2.87%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
157.59MMarket Cap
LossP/E TTM
More Details of Actuate Therapeutics Inc Company
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.
Actuate Therapeutics Inc Info
Ticker SymbolACTU
Company nameActuate Therapeutics Inc
IPO dateAug 13, 2024
CEOSchmitt (Daniel M)
Number of employees10
Security typeOrdinary Share
Fiscal year-endAug 13
Address1751 River Run
CityFORT WORTH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code76107
Phone18479864190
Websitehttps://actuatetherapeutics.com/
Ticker SymbolACTU
IPO dateAug 13, 2024
CEOSchmitt (Daniel M)
Company Executives of Actuate Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Andrew P. Mazar, Ph.D.
Dr. Andrew P. Mazar, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Todd Thomson
Mr. Todd Thomson
Independent Director
Independent Director
--
--
Mr. Paul Lytle
Mr. Paul Lytle
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jason A. Keyes
Mr. Jason A. Keyes
Independent Director
Independent Director
--
--
Dr. Daniel (Dan) Zabrowski, Ph.D.
Dr. Daniel (Dan) Zabrowski, Ph.D.
Independent Director
Independent Director
--
--
Dr. Aaron G. L. Fletcher, Ph.D.
Dr. Aaron G. L. Fletcher, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Amy Lynn Ronneberg
Ms. Amy Lynn Ronneberg
Independent Director
Independent Director
--
--
Mr. Daniel M. Schmitt
Mr. Daniel M. Schmitt
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Roger Sawhney, M.D.
Dr. Roger Sawhney, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Andrew P. Mazar, Ph.D.
Dr. Andrew P. Mazar, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Todd Thomson
Mr. Todd Thomson
Independent Director
Independent Director
--
--
Mr. Paul Lytle
Mr. Paul Lytle
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jason A. Keyes
Mr. Jason A. Keyes
Independent Director
Independent Director
--
--
Dr. Daniel (Dan) Zabrowski, Ph.D.
Dr. Daniel (Dan) Zabrowski, Ph.D.
Independent Director
Independent Director
--
--
Dr. Aaron G. L. Fletcher, Ph.D.
Dr. Aaron G. L. Fletcher, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bios Equity Partners, LP.
43.24%
Kairos Ventures LLC
11.33%
Voss Capital LLC
5.28%
Schmitt (Daniel M.)
2.66%
The Vanguard Group, Inc.
1.36%
Other
36.12%
Shareholders
Shareholders
Proportion
Bios Equity Partners, LP.
43.24%
Kairos Ventures LLC
11.33%
Voss Capital LLC
5.28%
Schmitt (Daniel M.)
2.66%
The Vanguard Group, Inc.
1.36%
Other
36.12%
Shareholder Types
Shareholders
Proportion
Venture Capital
43.24%
Corporation
11.33%
Hedge Fund
5.29%
Individual Investor
4.05%
Investment Advisor
3.07%
Investment Advisor/Hedge Fund
1.39%
Other Insider Investor
0.80%
Research Firm
0.15%
Pension Fund
0.03%
Other
30.65%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
79
12.03M
50.22%
-224.00
2025Q3
79
12.03M
50.22%
+808.23K
2025Q2
69
11.22M
52.70%
+720.24K
2025Q1
35
10.42M
53.60%
-51.23K
2024Q4
24
10.12M
53.12%
-258.89K
2024Q3
11
10.36M
0.00%
+10.36M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bios Equity Partners, LP.
9.97M
43.47%
-13.49K
-0.14%
Jun 30, 2025
Kairos Ventures LLC
2.63M
11.49%
--
--
Mar 31, 2025
Voss Capital LLC
286.14K
1.25%
+143.76K
+100.97%
Jun 30, 2025
Schmitt (Daniel M.)
619.01K
2.7%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
264.46K
1.15%
+245.89K
+1323.84%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
171.22K
0.75%
+164.19K
+2332.85%
Jun 30, 2025
Geode Capital Management, L.L.C.
118.05K
0.52%
+84.56K
+252.50%
Jun 30, 2025
Bios 2024 Co-Invest, L.P
125.00K
0.55%
+125.00K
--
Aug 14, 2024
Mazar (Andrew Paul)
115.47K
0.5%
+842.00
+0.73%
Mar 31, 2025
Northern Trust Investments, Inc.
84.79K
0.37%
+30.94K
+57.45%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Actuate Therapeutics Inc?
The top five shareholders of Actuate Therapeutics Inc are:
Bios Equity Partners, LP. holds 9.97M shares, accounting for 43.47% of the total shares.
Kairos Ventures LLC holds 2.63M shares, accounting for 11.49% of the total shares.
Voss Capital LLC holds 286.14K shares, accounting for 1.25% of the total shares.
Schmitt (Daniel M.) holds 619.01K shares, accounting for 2.70% of the total shares.
The Vanguard Group, Inc. holds 264.46K shares, accounting for 1.15% of the total shares.
Bios Equity Partners, LP. holds 9.97M shares, accounting for 43.47% of the total shares.
Kairos Ventures LLC holds 2.63M shares, accounting for 11.49% of the total shares.
Voss Capital LLC holds 286.14K shares, accounting for 1.25% of the total shares.
Schmitt (Daniel M.) holds 619.01K shares, accounting for 2.70% of the total shares.
The Vanguard Group, Inc. holds 264.46K shares, accounting for 1.15% of the total shares.
What are the top three shareholder types of Actuate Therapeutics Inc?
The top three shareholder types of Actuate Therapeutics Inc are:
Bios Equity Partners, LP.
Kairos Ventures LLC
Voss Capital LLC
Bios Equity Partners, LP.
Kairos Ventures LLC
Voss Capital LLC
How many institutions hold shares of Actuate Therapeutics Inc (ACTU)?
As of 2025Q4, 79 institutions hold shares of Actuate Therapeutics Inc, with a combined market value of approximately 12.03M, accounting for 50.22% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.00%.
What is the biggest source of revenue for Actuate Therapeutics Inc?
In --, the -- business generated the highest revenue for Actuate Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
